Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Current Deferred Revenue (2020 - 2025)

Rapid Micro Biosystems' Current Deferred Revenue history spans 6 years, with the latest figure at $4.7 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 28.79% to $4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.7 million, a 28.79% decrease, with the full-year FY2025 number at $4.7 million, down 28.79% from a year prior.
  • Current Deferred Revenue hit $4.7 million in Q4 2025 for Rapid Micro Biosystems, down from $5.1 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for RPID hit a ceiling of $6.6 million in Q4 2024 and a floor of $3.3 million in Q4 2021.
  • Historically, Current Deferred Revenue has averaged $4.9 million across 5 years, with a median of $4.7 million in 2022.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 42.61% in 2022 and later decreased 28.79% in 2025.
  • Tracing RPID's Current Deferred Revenue over 5 years: stood at $3.3 million in 2021, then surged by 42.61% to $4.7 million in 2022, then increased by 26.94% to $6.0 million in 2023, then increased by 10.48% to $6.6 million in 2024, then decreased by 28.79% to $4.7 million in 2025.
  • Business Quant data shows Current Deferred Revenue for RPID at $4.7 million in Q4 2025, $5.1 million in Q3 2025, and $6.1 million in Q2 2025.